Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD\/PD 2020","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Axon Neuroscience"},{"company":"Axon Neuroscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of its Vaccine-Induced Antibodies at Eurotau 2021","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CYPRUS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Axon Neuroscience"}]

Axon Neuroscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AXON Neuroscience Presented Results from its Phase II Clinical Trial Showing Multifold Therapeutic Effect of its Vaccine-Induced Antibodies at Eurotau 2021

Details:

Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.

Lead Product(s): AADvac1

Therapeutic Area: Neurology Product Name: AADvac1

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2021

ASK
US

Upload
your Pipeline Activity

Axon Neuroscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020

Details:

A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.

Lead Product(s): AADvac1

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY